Actinium Pharmaceuticals Company Profile (NYSEMKT:ATNM)

About Actinium Pharmaceuticals (NYSEMKT:ATNM)

Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $46.41 million
  • Outstanding Shares: 80,020,000
Average Prices:
  • 50 Day Moving Avg: $0.87
  • 200 Day Moving Avg: $1.27
  • 52 Week Range: $0.57 - $2.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.15 per share
  • Price / Book: 3.87
Profitability:
  • EBIDTA: ($28,170,000.00)
  • Return on Equity: -260.21%
  • Return on Assets: -181.24%
Misc:
  • Average Volume: 501,128 shs.
  • Short Ratio: 3.17
 

Frequently Asked Questions for Actinium Pharmaceuticals (NYSEMKT:ATNM)

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) announced its quarterly earnings results on Monday, March, 16th. The company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2017?

3 analysts have issued twelve-month target prices for Actinium Pharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $7.33 in the next year. View Analyst Ratings for Actinium Pharmaceuticals.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:

  • Sandesh Seth, Executive Chairman of the Board, Chief Executive Officer
  • Steve O'Loughlin, Principal Financial and Accounting Officer
  • Nitya G. Ray Ph.D., Executive Vice President, Head - Product Development, Manufacturing and Supply Chain
  • Steven Price, Vice President - Clinical and Commercial Strategy
  • Mark Stanley Berger, Chief Medical Officer
  • C. David Nicholson Ph.D., Independent Director
  • Ajit S. Shetty Ph.D., Independent Director
  • Richard I. Steinhart CPA, Independent Director

Who owns Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.67%), Virtu KCG Holdings LLC (0.76%), D.A. Davidson & CO. (0.22%) and Northern Trust Corp (0.18%). Company insiders that own Actinium Pharmaceuticals stock include Kaushik J Dave, Nitya G Ray, Richard I Steinhart, Sandesh Seth, Sergio Traversa, Sloan-Kettering Cance Memorial and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.

Who bought Actinium Pharmaceuticals stock? Who is buying Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Vanguard Group Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Kaushik J Dave, Nitya G Ray, Richard I Steinhart, Sandesh Seth, Sergio Traversa and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.

How do I buy Actinium Pharmaceuticals stock?

Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $0.58.


MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEMKT ATNM)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Actinium Pharmaceuticals (NYSEMKT:ATNM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33

Analysts' Ratings History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Show:
DateFirmActionRatingPrice TargetDetails
5/8/2017HC WainwrightReiterated RatingBuy$8.00View Rating Details
11/2/2016FBR & CoReiterated RatingBuy$9.00View Rating Details
10/21/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Earnings by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Earnings History by Quarter for Actinium Pharmaceuticals (NYSEMKT ATNM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.19)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-0.58 EPS

Dividends

Dividend History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Institutional Ownership by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Nitya G RayInsiderBuy10,000$0.75$7,500.00View SEC Filing  
8/2/2017Sandesh SethCEOBuy33,333$0.75$24,999.75View SEC Filing  
6/15/2017Sandesh SethChairmanBuy7,500$1.16$8,700.00View SEC Filing  
6/15/2017Steve O'loughlinInsiderBuy3,500$1.17$4,095.00View SEC Filing  
12/30/2016Sandesh SethInsiderBuy5,000$0.88$4,400.00View SEC Filing  
12/12/2016Sandesh SethInsiderBuy5,000$0.98$4,900.00View SEC Filing  
8/31/2016Sloan-Kettering Cance MemorialMajor ShareholderSell192,927$1.83$353,056.41View SEC Filing  
8/29/2016Sloan-Kettering Cance MemorialMajor ShareholderSell50,000$1.71$85,500.00View SEC Filing  
8/16/2016Sloan-Kettering Cance MemorialMajor ShareholderSell9,468$1.72$16,284.96View SEC Filing  
7/12/2016Sloan-Kettering Cance MemorialMajor ShareholderSell3,100$1.80$5,580.00View SEC Filing  
7/11/2016Sloan-Kettering Cance MemorialMajor ShareholderSell21,990$1.80$39,582.00View SEC Filing  
7/6/2016Sloan-Kettering Cance MemorialMajor ShareholderSell20,840$1.81$37,720.40View SEC Filing  
7/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell148,100$1.81$268,061.00View SEC Filing  
6/15/2016Sloan-Kettering Cance MemorialMajor ShareholderSell33,619$1.90$63,876.10View SEC Filing  
6/2/2016Sloan-Kettering Cance MemorialMajor ShareholderSell17,790$2.01$35,757.90View SEC Filing  
6/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell169,450$1.97$333,816.50View SEC Filing  
5/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell40,068$1.92$76,930.56View SEC Filing  
5/25/2016Sloan-Kettering Cance MemorialMajor ShareholderSell36,400$1.90$69,160.00View SEC Filing  
4/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell52,577$2.04$107,257.08View SEC Filing  
4/21/2016Sloan-Kettering Cance MemorialMajor ShareholderSell196,497$2.03$398,888.91View SEC Filing  
4/18/2016Sandesh SethChairmanBuy15,000$1.99$29,850.00View SEC Filing  
4/15/2016Sergio TraversaDirectorBuy3,000$2.02$6,060.00View SEC Filing  
4/14/2016Kaushik J DaveCEOBuy10,000$2.02$20,200.00View SEC Filing  
4/14/2016Richard I SteinhartDirectorBuy2,500$2.01$5,025.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Latest Headlines for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Source:
DateHeadline
globenewswire.com logoActinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17 ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:18 PM
finance.yahoo.com logoActinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
finance.yahoo.com - August 9 at 4:18 PM
americanbankingnews.com logoInsider Buying: Actinium Pharmaceuticals Inc (ATNM) CEO Acquires 33,333 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM
finance.yahoo.com logoActinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - August 2 at 4:58 PM
benzinga.com logoMid-Afternoon Market Update: CyberOptics Drops After Q2 Results; Aaron's Shares Surge - Benzinga
www.benzinga.com - July 29 at 3:50 PM
finance.yahoo.com logoActinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - July 28 at 5:25 PM
streetinsider.com logoActinium Pharma (ATNM) Plans Offering of Common Stock and Warrants
www.streetinsider.com - July 28 at 2:07 AM
streetinsider.com logoActinium Pharma (ATNM) Plans Offering of Common Stock and Warrants - StreetInsider.com
www.streetinsider.com - July 28 at 1:55 AM
finance.yahoo.com logoActinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
finance.yahoo.com - July 27 at 8:54 PM
globenewswire.com logoActinium Pharmaceuticals to Host Webinar Focused on Actimab-A ... - GlobeNewswire (press release)
globenewswire.com - July 6 at 5:30 PM
nasdaq.com logoActinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD
www.nasdaq.com - July 6 at 5:29 PM
finance.yahoo.com logoActinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
finance.yahoo.com - July 6 at 5:29 PM
americanbankingnews.com logoActinium Pharmaceuticals Inc (ATNM) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - June 20 at 5:30 PM
streetinsider.com logoActinium Pharma (ATNM) Publishes Letter to Shareholders Highlighting Accomplishments & Upcoming Catalysts - StreetInsider.com
www.streetinsider.com - June 15 at 10:27 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Nitya Ray Ph.D. as EVP, Head of ... - StreetInsider.com
www.streetinsider.com - June 15 at 5:25 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Nitya Ray Ph.D. as EVP, Head of Product Development, Manufacturing & Supply Chain
www.streetinsider.com - June 15 at 5:24 PM
finance.yahoo.com logoActinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
finance.yahoo.com - June 15 at 5:24 PM
finance.yahoo.com logoActinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
finance.yahoo.com - June 15 at 5:24 PM
globenewswire.com logoActinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B - GlobeNewswire (press release)
globenewswire.com - June 12 at 4:44 PM
nasdaq.com logoActinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer - Nasdaq
www.nasdaq.com - June 9 at 9:20 PM
streetinsider.com logoActinium Pharma (ATNM) Names Sandesh Seth as CEO - StreetInsider.com
www.streetinsider.com - June 9 at 4:18 PM
finance.yahoo.com logoActinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
finance.yahoo.com - June 9 at 4:04 PM
globenewswire.com logoUPDATE – Actinium Pharmaceuticals to Host Webinar on June 12th ... - GlobeNewswire (press release)
globenewswire.com - June 8 at 4:27 PM
finance.yahoo.com logoActinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
finance.yahoo.com - June 8 at 4:27 PM
nasdaq.com logoActinium Pharmaceuticals to Host Webinar on June 12th to Update ... - Nasdaq
www.nasdaq.com - May 31 at 3:43 PM
globenewswire.com logoActinium Pharmaceuticals to Host Webinar on June 12th to Update ... - GlobeNewswire (press release)
globenewswire.com - May 31 at 10:51 AM
finance.yahoo.com logoActinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
finance.yahoo.com - May 31 at 10:51 AM
streetinsider.com logoActinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A
www.streetinsider.com - May 24 at 10:27 AM
streetinsider.com logoActinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A - StreetInsider.com
www.streetinsider.com - May 24 at 9:51 AM
finance.yahoo.com logoActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
finance.yahoo.com - May 24 at 9:51 AM
globenewswire.com logoActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy - GlobeNewswire (press release)
globenewswire.com - May 23 at 9:29 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma
www.bizjournals.com - May 19 at 9:22 AM
streetinsider.com logoActinium Pharma (ATNM) CEO and CTO Resign
www.streetinsider.com - May 16 at 8:49 PM
streetinsider.com logoActinium Pharma (ATNM) CEO and CTO Resign - StreetInsider.com - StreetInsider.com
www.streetinsider.com - May 16 at 8:49 PM
finance.yahoo.com logoAnthem Denies Cigna Breakup Fee as Merger Bid Crumbles
finance.yahoo.com - May 12 at 4:17 PM
streetinsider.com logoActinium Pharma (ATNM) Says It's Cleared by Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - StreetInsider.com
www.streetinsider.com - May 11 at 4:07 PM
reuters.com logoBRIEF-Actinium Pharmaceuticals files for non-timely 10-Q
www.reuters.com - May 11 at 4:07 PM
nasdaq.com logoActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - Nasdaq
www.nasdaq.com - May 10 at 9:05 AM
finance.yahoo.com logoActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
finance.yahoo.com - May 10 at 9:04 AM
americanbankingnews.com logoActinium Pharmaceuticals Inc (ATNM) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - May 8 at 9:36 PM
americanbankingnews.com logoActinium Pharmaceuticals (ATNM) Given Media Impact Score of 0.22
www.americanbankingnews.com - April 29 at 10:52 AM
finance.yahoo.com logoActinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
finance.yahoo.com - April 18 at 10:11 AM
biz.yahoo.com logoACTINIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial
biz.yahoo.com - March 28 at 8:40 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors - StreetInsider.com
www.streetinsider.com - March 28 at 3:40 PM
streetinsider.com logoActinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors
www.streetinsider.com - March 28 at 11:37 AM
finance.yahoo.com logoActinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
finance.yahoo.com - March 28 at 11:37 AM
bizjournals.com logoHow These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences
www.bizjournals.com - March 27 at 9:01 AM
investopedia.com logoMoleculin Leukemia Drug Gets Orphan Status (MBRX)
www.investopedia.com - March 22 at 4:13 PM
us.rd.yahoo.com logoActinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
us.rd.yahoo.com - March 21 at 12:32 PM
streetinsider.com logoActinium Pharma (ATNM) Announces Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and Technology Platform
www.streetinsider.com - March 1 at 6:25 AM

Social

This page was last updated on 8/18/2017 by MarketBeat.com Staff